Literature DB >> 15097978

Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa.

Toshio Hasegawa, Yasushi Suga, Masayuki Mizoguchi, Shigaku Ikeda, Hideoki Ogawa, Kentaro Kubo, Hiromichi Matsui, Shizuko Kagawa, Yoshimitsu Kuroyanagi.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15097978     DOI： 10.1016/j.jaad.2003.08.013

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  15 in total

1.  Comparative evaluation of re-epithelialization promoted by fresh or cryopreserved cultured dermal substitute.

Authors:  Naoto Yamada; Eiju Uchinuma; Yasuhiro Matsumoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-12-17       Impact factor: 1.731

2.  A case of lower-extremity deep burn wounds with periosteal necrosis successfully treated by use of allogenic cultured dermal substitute.

Authors:  Naoki Ohara; Shoji Mihara; Hiroyuki Nihara; Narihiro Akimoto; Naoki Madokoro; Mikio Kawai; Hideki Noda; Michihiro Hide; Yasuhiro Matsumoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2010-03-27       Impact factor: 1.731

3.  Skin substitutes based on allogenic fibroblasts or keratinocytes for chronic wounds not responding to conventional therapy: a retrospective observational study.

Authors:  Giorgio Pajardi; Vicenzo Rapisarda; Francesco Somalvico; Andrea Scotti; Giulia Lo Russo; Francesco Ciancio; Arturo Sgrò; Manuela Nebuloni; Raffaele Allevi; Maria L Torre; Emilio Trabucchi; Mario Marazzi
Journal:  Int Wound J       Date:  2014-02-12       Impact factor: 3.315

4.  Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers.

Authors:  Naoto Yamada; Eiju Uchinuma; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2011-12-03       Impact factor: 1.731

Review 5.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

6.  Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-beta, and IL-8.

Authors:  Akiko Hashimoto; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-12-17       Impact factor: 1.731

7.  Application of cultured dermal substitute for amelioration of maxillary bone growth suppression after cleft palate operation in rats.

Authors:  Norifumi Kurokawa; Koichi Ueda; Motomu Tsuji; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-12-17       Impact factor: 1.731

8.  Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of the lower leg.

Authors:  Naoto Yamada; Eiju Uchinuma; Yoshimitsu Kuroyanagi
Journal:  J Artif Organs       Date:  2008-07-06       Impact factor: 1.731

Review 9.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

10.  Biologicals and fetal cell therapy for wound and scar management.

Authors:  Nathalie Hirt-Burri; Albert-Adrien Ramelet; Wassim Raffoul; Anthony de Buys Roessingh; Corinne Scaletta; Dominique Pioletti; Lee Ann Applegate
Journal:  ISRN Dermatol       Date:  2011-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.